ArticleJournal of virology2013
A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 77 citations in OpenAlex.
- E2 Protein of Chikungunya Virus: A Narrative Review of Its Potential as a Therapeutic Target.Current drug targets · 2026Review
- Chikungunya virus and other emerging arthritogenic alphaviruses.Nature reviews. Microbiology · 2025Review
- γδ T Cells Mediate Protective Immunity Following Vaccination with an Insect-Based Chikungunya Fever Vaccine in Mice.Pathogens (Basel, Switzerland) · 2025Article
- Article
- VSV-CHIKV activates antitumor immunity by inducing pyroptosis in a melanoma model.Discover oncology · 2025Article
- Review
- Revolutionizing Chikungunya Vaccines: mRNA Breakthroughs With Molecular and Immune Simulations.Bioinformatics and biology insights · 2025Article
- A safe insect-based chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques.NPJ vaccines · 2024Article
- Chikungunya fever.Nature reviews. Disease primers · 2023Review
- Chikungunya Virus: Priority Pathogen or Passing Trend?Vaccines · 2023Review
- Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to theExperimental and therapeutic medicine · 2023Review
- Generation of a Live-Attenuated Strain of Chikungunya Virus from an Indian Isolate for Vaccine Development.Vaccines · 2022Article
- Construction and Evaluation of Recombinant Adenovirus Candidate Vaccines for Chikungunya Virus.Viruses · 2022Article
- The emerging roles of retromer and sorting nexins in the life cycle of viruses.Virologica Sinica · 2022Review
- Chikungunya Vaccine Candidates: Current Landscape and Future Prospects.Drug design, development and therapy · 2022Review
- Article
- Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape.Microorganisms · 2021Review
- Chikungunya: an emerging rheumatological pandemic?Current rheumatology research · 2021Article
- Chikungunya Virus Evades Antiviral CD8Journal of virology · 2020Article
- Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
While a large number of mosquito-transmitted alphaviruses are known to cause serious human diseases, there are no licensed vaccines that protect against alphavirus infections. The alphavirus chikungunya virus (CHIKV) has caused multiple recent outbreaks of chikungunya fever. This virus has the potential to cause a worldwide epidemic and has generated strong interest in development of a prophylactic CHIKV vaccine. We report here on the development of a potent experimental vaccine for CHIKV based on a chimeric vesicular stomatitis virus (VSV) expressing the entire CHIKV envelope polyprotein (E3-E2-6K-E1) in place of the VSV glycoprotein (G). These VSVΔG-CHIKV chimeras incorporated functional CHIKV glycoproteins into the viral envelope in place of VSV G. The chimeric viruses were attenuated for growth in tissue culture but could be propagated to high titers without VSV G complementation. They also generated robust neutralizing antibody and cellular immune responses to CHIKV in mice after a single dose and protected mice against CHIKV infection. VSVΔG-alphavirus chimeras could have general applicability as alphavirus vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.